Trial Profile
A Phase II,Randomized, Double-Blind, Flexible Dose Study of ZP120 I.V. Infusion as Add-On Therapy in Patients With Acute or Sub-Acute Decompensated Chronic Heart Failure NYHA Class III-IV Treated With Furosemide.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2018
Price :
$35
*
At a glance
- Drugs SER 100 (Primary) ; Furosemide
- Indications Decompensated heart failure
- Focus Therapeutic Use
- Sponsors Zealand Pharma
- 15 Oct 2006 New trial record.